Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

Santhera (Group)

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of severe neuromuscular and neurodegenerative diseases, an area of high unmet medical need which includes many orphan and niche indications with no current therapy. Santhera's first product, Catena® to treat Friedreich's Ataxia is marketed in Canada. *

 

Period Start 2004-09-08 merged
  Today Santhera Pharmaceuticals AG
  Predecessor Graffinity Pharmaceuticals AG
Product Industry BIOTECH
Person Person Meier, Thomas (Viopas Venture Consulting 202201 Managing Partner before Santhera Pharmaceuticals)
     
Region Region Liestal BL
  Country Switzerland
  Street 24 Hohenrainstr.
  City 4133 Pratteln
  Tel +41-61-906-8950
    Address record changed: 2023-11-02
     
Basic data Employees D: 101 to 500 (2017-12-31)
  Currency CHF
  Annual sales 22,943,000 (sales, net, consolidated (2017) 2017-12-31)
  Profit -51,532,000 (2017-12-31)
  Cash 45,195,000 (2017-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Santhera (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px




» top